%0 Journal Article
%T Mitochondrial mutations and metabolic adaptation in pancreatic cancer
%A Andrew J. Hoy
%A Andrew V. Biankin
%A Australian Pancreatic Cancer Genome Initiative
%A Darren N. Saunders
%A David Miller
%A Ellen van Dam
%A Jessie McKenna
%A John V. Pearson
%A Leonid Sazanov
%A Marina Pajic
%A Mark Cowley
%A Mark Pinese
%A Mary Iconomou
%A Nicola Waddell
%A Nigel Turner
%A Rae-Anne Hardie
%A Robert F. Shearer
%A Sean M. Grimmond
%A Seher Balaban
%A Silas Villas-Boas
%A Ting-Li Han
%J Archive of "Cancer & Metabolism".
%D 2017
%R 10.1186/s40170-017-0164-1
%X Pancreatic cancer has a five-year survival rate of ~8%, with characteristic molecular heterogeneity and restricted treatment options. Targeting metabolism has emerged as a potentially effective therapeutic strategy for cancers such as pancreatic cancer, which are driven by genetic alterations that are not tractable drug targets. Although somatic mitochondrial genome (mtDNA) mutations have been observed in various tumors types, understanding of metabolic genotype-phenotype relationships is limited
%K Pancreas
%K Mitochondria
%K Metabolomics
%K Glutamine
%K Lipid
%K Genome
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282905/